Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Creators: name: Fendler, Annika
name: Shepherd, Scott TC
name: Au, Lewis
name: Wilkinson, Katalin A
name: Wu, Mary
name: Byrne, Fiona
name: Cerrone, Maddalena
name: Schmitt, Andreas M
name: Joharatnam-Hogan, Nalinie
name: Shum, Benjamin
name: Tippu, Zayd
name: Rzeniewicz, Karolina
name: Boos, Laura Amanda
name: Harvey, Ruth
name: Carlyle, Eleanor
name: Edmonds, Kim
name: Del Rosario, Lyra
name: Sarker, Sarah
name: Lingard, Karla
name: Mangwende, Mary
name: Holt, Lucy
name: Ahmod, Hamid
name: Korteweg, Justine
name: Foley, Tara
name: Bazin, Jessica
name: Gordon, William
name: Barber, Taja
name: Emslie-Henry, Andrea
name: Xie, Wenyi
name: Gerard, Camille L
name: Deng, Daqi
name: Wall, Emma C
name: Agua-Doce, Ana
name: Namjou, Sina
name: Caidan, Simon
name: Gavrielides, Mike
name: MacRae, James I
name: Kelly, Gavin
name: Peat, Kema
name: Kelly, Denise
name: Murra, Aida
name: Kelly, Kayleigh
name: O’Flaherty, Molly
name: Dowdie, Lauren
name: Ash, Natalie
name: Gronthoud, Firza
name: Shea, Robyn L
name: Gardner, Gail
name: Murray, Darren
name: Kinnaird, Fiona
name: Cui, Wanyuan
name: Pascual, Javier
name: Rodney, Simon
name: Mencel, Justin
name: Curtis, Olivia
name: Stephenson, Clemency
name: Robinson, Anna
name: Oza, Bhavna
name: Farag, Sheima
name: Leslie, Isla
name: Rogiers, Aljosja
name: Iyengar, Sunil
name: Ethell, Mark
name: Messiou, Christina
name: Cunningham, David
name: Chau, Ian
name: Starling, Naureen
name: Turner, Nicholas
name: Welsh, Liam
name: van As, Nicholas
name: Jones, Robin L
name: Droney, Joanne
name: Banerjee, Susana
name: Tatham, Kate C
name: O’Brien, Mary
name: Harrington, Kevin
name: Bhide, Shreerang
name: Okines, Alicia
name: Reid, Alison
name: Young, Kate
name: Furness, Andrew JS
name: Pickering, Lisa
name: Swanton, Charles
name: Consortium, The Crick COVID-19
name: Gandhi, Sonia
name: Gamblin, Steve
name: Bauer, David LV
name: Kassiotis, George
name: Kumar, Sacheen
name: Yousaf, Nadia
name: Jhanji, Shaman
name: Nicholson, Emma
name: Howell, Michael
name: Walker, Susanna
name: Wilkinson, Robert J
name: Larkin, James
name: Turajlic, Samra
name: Consortium, The CAPTURE
Publisher: name: The Francis Crick Institute
Year: 2022
Subjects: subject: Neurosciences
subject: FOS: Clinical medicine
subject: Model organisms
subject: Biochemistry &amp; Proteomics
subject: Tumour Biology
subject: Signalling &amp; Oncogenes
subject: Genetics &amp; Genomics
subject: Developmental Biology
subject: Genome Integrity &amp; Repair
subject: Human Biology &amp; Physiology
subject: Structural Biology &amp; Biophysics
subject: Cell Biology
subject: Cell Cycle &amp; Chromosomes
subject: Stem Cells
subject: Chemical Biology &amp; High Throughput
subject: Infectious Disease
subject: Ecology,Evolution &amp; Ethology
subject: Immunology
subject: Metabolism
subject: Computational &amp; Systems Biology

description: Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.